在患有良性前列腺增生症的患者中,tamsulosine的种群药理学
Valentina N Nikolic1, Slobodan M Jankovic2, Maja Vujovic3
1Department of Pharmacology with Toxicology, University of Nis Faculty of Medicine, Bul. dr Zorana Djindjica 81, Nis 1800, Serbia. valentina@medfak.ni.ac.rs.
World journal of urology
|July 22, 2024
概括
在良性前列腺增生症 (BPH) 患者中,tamsulosin 清除值为 0.719 L/h,血红蛋白水平较高与清除值增加相关. 这表明患者特异性因素影响BPH管理中的tamsulosin消除.
科学领域:
- 药理动力学 药理动力学
- 药理学 药理学是指药理学的学科.
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
背景情况:
- 良性前列腺增生症 (BPH) 是老年男性常见的疾病.
- 与BPH相关的下尿路症状 (LUTS) 显著影响生活质量.
- 坦素是BPH治疗中广泛使用的α-阻断剂.
研究的目的:
- 为了确定BPH患者的典型tamsulosin清除和分布体积.
- 为了确定影响该群体中tamsulosin消除的因素.
- 了解tamsulosin在BPH中的药理动力学变异性.
主要方法:
- 开放标签,单臂人群的药理动力学研究.
- 65名患有BPH的成年男性正在接受坦素治疗.
- 用LC-MS/MS测量的血清度;用NONMEM分析的数据.
主要成果:
- 坦素清除值估计为0.719 L/h;分布体积为32 L.
- 和肝功能没有显著影响清除.
- 血红蛋白水平与坦苏素清除呈正相关性.
结论:
- 坦苏洛辛的药理动力学与LUTS/BPH患者的特征有关.
- 血红蛋白水平与LUTS/BPH患者的坦素清除有关.
- 强调在治疗BPH时考虑个体患者因素的重要性.
相关概念视频
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
113
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
113
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
142
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
142
Renal Failure: Dose Adjustments
78
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
78
Nonlinear Pharmacokinetics: Bioavailability and Protein-Drug Binding
149
When a drug follows nonlinear pharmacokinetics, its bioavailability, the amount of the drug that reaches the systemic circulation, can change with different doses. This is due to the presence of a saturable pathway. The pathway becomes saturated as the drug concentration increases, decreasing the absorption rate. Consequently, the drug's bioavailability may be lower than expected at higher doses.
To quantify the extent of bioavailability, pharmacologists often use a parameter called .
To quantify the extent of bioavailability, pharmacologists often use a parameter called .
149
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
55
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
55
Noncompartmental Analysis: Miscellaneous Pharmacokinetic Parameters
81
The noncompartmental approach is a widely used method in pharmacokinetics to assess drugs' behaviors in the body. It considers several factors, including clearance, bioavailability, and total volume of distribution.
One key aspect of the noncompartmental approach is determining a drug's total clearance. This can be done by dividing the drug dose by the area under the concentration-time curve from zero to infinity. The area under the concentration-time curve represents the drug's...
One key aspect of the noncompartmental approach is determining a drug's total clearance. This can be done by dividing the drug dose by the area under the concentration-time curve from zero to infinity. The area under the concentration-time curve represents the drug's...
81


